Analysts Set Novo Nordisk A/S (NYSE:NVO) PT at $145.25

Novo Nordisk A/S (NYSE:NVO) has received an average rating of “Buy” from the seven brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $145.25.

A number of analysts recently issued reports on the stock. BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th.

Institutional Investors Weigh In On Novo Nordisk A/S

A number of hedge funds have recently bought and sold shares of NVO. AQR Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 110.5% during the second quarter. AQR Capital Management LLC now owns 17,164 shares of the company’s stock worth $2,450,000 after purchasing an additional 9,012 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in Novo Nordisk A/S by 45.8% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 23,664 shares of the company’s stock worth $3,378,000 after buying an additional 7,430 shares during the last quarter. Centaurus Financial Inc. grew its position in shares of Novo Nordisk A/S by 98.5% in the 2nd quarter. Centaurus Financial Inc. now owns 7,175 shares of the company’s stock worth $1,024,000 after acquiring an additional 3,560 shares in the last quarter. Eldred Rock Partners LLC increased its holdings in shares of Novo Nordisk A/S by 118.7% in the 3rd quarter. Eldred Rock Partners LLC now owns 91,174 shares of the company’s stock valued at $10,856,000 after acquiring an additional 49,484 shares during the last quarter. Finally, Collective Family Office LLC raised its position in shares of Novo Nordisk A/S by 10.5% during the 3rd quarter. Collective Family Office LLC now owns 6,416 shares of the company’s stock valued at $764,000 after acquiring an additional 610 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $87.16 on Friday. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15. The firm’s 50 day moving average is $92.24 and its two-hundred day moving average is $112.01. The company has a market cap of $391.15 billion, a P/E ratio of 28.21, a P/E/G ratio of 0.93 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 86.32% and a net margin of 35.03%. Analysts expect that Novo Nordisk A/S will post 3.16 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a $0.7874 dividend. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s payout ratio is 23.30%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.